Hormonal
Resveratrol acts as a phytoestrogen by binding to estrogen receptors (ER-α and ER-β), but its affinity is 7000 times weaker than estradiol, and it acts as an antagonist in some tissues (e.g., uterus in rats) while showing agonist activity in others (e.g., MCF-7 breast cancer cells).
Resveratrol has a chemical structure similar to estrogen, but it binds to estrogen receptors very weakly. In some tissues, it may even block estrogen's effects. For most people, this interaction is negligible, but those with hormone-sensitive conditions should consult a doctor.
In fact, resveratrol is able to bind to estrogen receptors alpha and beta (ER-𝛼 and ER-𝛽) with similar affinities, but this interaction is 7000 times less powerful than that of estradiol [58].
Why this rating
Supported by multiple in vitro and in vivo studies cited (refs 58-63).
Source
Properties of Resveratrol:<i>In Vitro</i>and<i>In Vivo</i>Studies about Metabolism, Bioavailability, and Biological Effects in Animal Models and Humans
Juan Gambini et al. · Oxidative Medicine and Cellular Longevity · 2015
DOI 10.1155/2015/837042
More from this paper
- Resveratrol exhibits low oral bioavailability of the free compound in humans, with plasma concentrations of free resveratrol remaining below 10 ng/mL (<40 nM) even after high-dose supplementation, while metabolites reach significantly higher concentrations.Good
- Resveratrol extends lifespan in invertebrate models (yeast, C. elegans, Drosophila) by activating sirtuins (specifically Sir2/SIRT1), mimicking the effects of calorie restriction, though this mechanism is controversial in vertebrates and humans.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →